This historic milestone marks an important step forward.
We are pleased to announce that CASGEVY™ (exagamglogene autotemcel), a CRISPR/Cas9 gene-edited therapy arising out of our collaboration with Vertex Pharmaceuticals Incorporated, has now been approved in some countries for certain eligible patients with sickle cell disease or transfusion-dependent beta thalassemia.
Vertex is the manufacturer and exclusive license holder of CASGEVY™. The CASGEVY™ word mark and design are trademarks of Vertex Pharmaceuticals Incorporated.
You are now leaving the CRISPR Therapeutics website.
CRISPR Therapeutics is not responsible for the content or availability of third-party sites.